In 2026, the India Keytruda market is witnessing a revolution in Biomarker-Driven Patient Selection. In 2026, oncologists across the country are identifying "PD-L1 Testing" and "MSI-High" status as mandatory precursors to prescribing Keytruda, ensuring that the drug is only given to those most likely to respond. This 2026 movement is significant because it optimizes the cost-effectiveness of the treatment, preventing families from spending lakhs on a therapy that may not be biologically suitable for their specific tumor type. By 2026, the "Diagnostic Partnership" between pharma companies and labs like Dr. Lal PathLabs is recognized as a standard part of the immunotherapy journey in India.

The drive for precision medicine is a high-value driver within the India Keytruda Market. In 2026, "Monotherapy" still accounts for a large portion of prescriptions, but "Adjuvant Therapy"—given after surgery to prevent recurrence—is identified as a key growth area this year. This 2026 trend is also being fueled by the "Digital Pathology" surge, where AI algorithms analyze biopsy slides to detect PD-L1 expression levels with 99% accuracy. The 2026 market shows that by being smarter about who gets the drug, India is achieving better clinical outcomes even within a limited healthcare budget.

Do you think that the government should make biomarker testing free for all cancer patients to ensure they get the right treatment first? Please leave a comment!

#PrecisionMedicine #Biomarkers2026 #SmartDiagnostics #PDL1 #IndiaOncology